141st APHA Annual Meeting

In This section

285682
Mortality among people with hepatitis c and HCV/HIV co-infection in New York city, 2000-2011

Monday, November 4, 2013

Jessie Pinchoff, PhD candidate, MPH , Division of Disease Control, NYC Department of Health and Mental Hygiene, Long Island City, NY
Ann Drobnik, MPH , Division of Disease Control, NYC Department of Health and Mental Hygiene, Long Island City, NY
Jennifer Fuld, PhD candidate, MA , Division of Disease Control, NYC Department of Health and Mental Hygiene, Long Island City, NY
Sarah Braunstein, PhD MPH , HIV/AIDS Epidemiology and Field Services, New York City Department of Health and Mental Hygiene, Long Island City, NY
Katherine Bornschlegel, MPH , Bureau of Communicable Disease, New York City Department of Health and Mental Hygiene, Long Island City, NY
Jay K. Varma, MD , National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control & Prevention CDC, Atlanta, GA
Background: Persons with hepatitis C (HCV)/HIV co-infection are at greater risk of death than those with HCV only, but the impact of HIV on mortality among people with HCV has not been well studied in New York City (NYC). We analyzed mortality trends and risk of death among persons with HCV alone, and HCV/HIV-co-infection in NYC.

Methods: The NYC Department of Health and Mental Hygiene (DOHMH) implemented CDC's Program Collaboration and Service Integration initiative to better understand the interaction between infectious diseases in NYC. We conducted a retrospective, deterministic cross-match of HIV and HCV surveillance databases with data from 2000-2010, and NYC death registry data from 2000-2011. We examined changes in the proportion of HCV cases with HIV over time, and used survival analysis to compare progression to death in the two groups over the 10-year period, controlling for age.

Results: Of persons diagnosed with HCV in 2000, 8% were diagnosed with HIV. This proportion of co-infected HCV cases increased to 17% in 2010. During the study period, 19% of HCV/HIV co-infected persons died within 3 years of their HCV diagnosis, compared with 9% of persons with HCV only (<.0001). The annual risk of death was 5.5 times higher for co-infected cases compared with the HCV-only group (p<.0001).

Conclusion: Given the higher risk of death among persons with HCV/HIV co-infection, the NYC DOHMH is developing a strategy to improve HCV testing among people with HIV, and to prioritize linkage to medical care for co-infected persons who are not in care.

Learning Areas:
Chronic disease management and prevention
Epidemiology
Public health or related research

Learning Objectives:
Describe how surveillance and vital records data can be used for population level analysis of HCV/HIV co-infection

Keywords: Hepatitis C, Surveillance

Presenting author's disclosure statement:

Not Answered